Protective effect of Asarum extract in rats with adjuvant arthritis

WENQIANG ZHANG¹, JUAN ZHANG², MING ZHANG¹ and LIN NIE³

¹Department of Orthopedics, Shandong Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014; ²Department of Cardiology, No. 2 Hospital Affiliated to Shandong University, Jinan, Shandong 250033; ³Department of Orthopedics, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China

Received February 18, 2014; Accepted August 4, 2014

DOI: 10.3892/etm.2014.1941

Abstract. The aim of the present study was to investigate the protective effect of Asarum extract on rats with adjuvant arthritis (AA) and to determine the underlying mechanism. An AA model was established by injecting Freund’s complete adjuvant into the rats. The degree of toe swelling, arthritis index, spleen index, and the expression levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 were measured. In addition, the underlying molecular mechanism was investigated using murine macrophage-derived RAW 264.7 cells. Asarum extract was found to significantly reduce the severity of arthritis by decreasing hind paw swelling, the arthritis index, the spleen index, and TNF-α, IL-1β and IL-6 expression levels in plasma. In vitro, Asarum extract inhibited the nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling pathways. These results indicate that Asarum extract may be a therapeutic agent for AA and may exert an anti-inflammatory effect by mediating the NF-κB and MAPK signaling pathways.

Introduction

Rheumatoid arthritis (RA) is a chronic, disabling and systemic autoimmune disease that leads to joint inflammation, as well as progressive cartilage and bone erosion (1-3). RA also causes tissue inflammation around the joints and other organs of the body. The disease affects up to 1% of the adult population worldwide (4).

Freund’s complete adjuvant (FCA)-induced arthritis shares a number of characteristics with RA (5). FCA mirrors the pathology of RA, by causing hyperplasia of the synovial tissues, inflammatory infiltration of the joints, and the destruction of bone and cartilage.

Asarum, a traditional Chinese medicine known as ‘xixin’, is widely distributed in the north-east of China (6). The herb has been used for the treatment of colds, and as an analgesic, antitussive or anti-allergic remedy. Modern pharmacological studies have shown that Asarum species exhibit anti-inflammatory, antitussive, anti-allergic, anti-hyperlipidemic and anti-myocardiac ischemia properties by enhancing myocardial contractility, antiarrhythmic activities and other mechanisms (7,8).

In the present study, the anti-arthritic activity of Asarum extracts in rats with FCA-induced adjuvant arthritis was evaluated and the anti-inflammatory mechanisms in lipopolysaccharide (LPS)-treated RAW 264.7 macrophages were explored. The underlying mechanism was also investigated.

Materials and methods

Materials. Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum and the antibiotic-antimycotic solution were purchased from Gibco (Auckland, New Zealand). The ELISA kits for TNF-α, IL-1β and IL-6 were obtained from Neobioscience (Beijing, China). Primary antibodies against extracellular signal-regulated kinase (ERK), phospho-ERK, p38, phospho-p38, c-Jun N-terminal kinase (JNK), phospho-JNK, IκB-α, phospho-IκB-α, p65, phospho-p65, IKKβ and phospho-IKKβ were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were also obtained from Cell Signaling Technology.

Induction of adjuvant arthritis (AA). Sprague-Dawley rats (250-300 g; obtained from Vital River Laboratories, Beijing, China) were maintained under conditions of standard lighting (an alternating 12 h light/dark cycle), temperature (23-25˚C) and humidity (40-70%). The rats were immunized (day 0) with 1 ml sterile Bacillus Calmette-Guérin (BCG) with 1 ml sterile paraffin oil. Control animals received 0.1 ml saline (0.9% NaCl solution). This study was performed in accordance with the recommendations from the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health [Eighth Edition (2011); Bethesda, MD, USA]. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Shandong University (Jinan, China).

Correspondence to: Professor Lin Nie, Department of Orthopedics, Qilu Hospital Affiliated to Shandong University, 107 West Wenhua Street, Jinan, Shandong 250012, P.R. China. E-mail: linniecn@126.com

Key words: adjuvant arthritis, rheumatoid arthritis
**Table I. Effect of Asarum extracts on swelling scores in rats with adjuvant-induced arthritis (mean ± standard deviation).**

| Groups            | n  | Day 14     | Day 18     | Day 22     | Day 26     | Day 30     |
|-------------------|----|------------|------------|------------|------------|------------|
| Control           | 12 | 0          | 0          | 0          | 0          | 0          |
| Model             | 12 | 0.67±0.65  | 1.25±0.75  | 2.5±1.51   | 2.42±1.51  | 2.25±1.22  |
| GTW, 40 mg/kg     | 12 | 0.58±0.67  | 1±0.85     | 1.42±1.31  | 1.25±1.22b | 1.17±0.94b |
| Asarum extract    |    |            |            |            |            |            |
| 20 mg/kg          | 12 | 0.67±0.65  | 1.17±0.58  | 1.67±0.89  | 1.67±1.15  | 1.42±0.99  |
| 40 mg/kg          | 12 | 0.58±0.67  | 1.08±0.79  | 1.58±1.08  | 1.5±1.17   | 1.33±0.89b |
| 80 mg/kg          | 12 | 0.58±0.67  | 1±0.60     | 1.5±1      | 1.33±0.98b | 1.25±0.87b |

*P<0.01 versus control group; bP<0.05 and *P<0.01, versus model group. GTW, glycoside of *Tripterygium wilfordii*.

**Grouping.** Treatment with the test agent began on day 7. All treatments were orally administered to the rats. Rats were divided into six groups: Group 1, normal control; Group 2, arthritis control; Group 3, glycoside of *Tripterygium wilfordii* (GTW) 40 mg/kg/day; Group 4, *Asarum* extract-low dose (L) 20 mg/kg/day; Group 5, *Asarum* extract-medium dose (M) 40 mg/kg/day; and Group 6, *Asarum* extract-high dose (H) 80 mg/kg/day. GTW was purchased from Shanghai Fudan Forward Pharmaceutical Co., Ltd. (Shanghai, China). *Ansarum* extract was extracted and prepared in the Medical Experimental Center of Shandong Qianfoshan Hospital (Jinan, Shandong).

**Evaluation of AA.** Paw volumes were recorded on days 14, 18, 22, 26 and 30. The arthritis index (AI) was classified using a five-value scale: 0, no swelling; 1 point, swelling on the joint of the little toe; 2 points, swelling on the metatarsal phalanx joint and foot; 3 points, swelling on the hind paw excluding the ankle; and 4 points, swelling on the hind paw and ankle. The sum of points for each rat was then calculated.

The hind paw volume (ml) of all animal groups was measured by a plethysmometer on days 14, 18, 22, 26 and 30 after the injection of FCA emulsion. The paw swelling rate (%) was expressed as increased multiples of right hind paw volume by subtraction of the basic paw volume, as a proportion of the basic paw volume.

The ratio of spleen weight to rat body weight represented the spleen index. Blood was collected from the retro-orbital plexus for measurement of biochemical and hematological parameters, namely tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6.

**Cell cultures.** The RAW 264.7 murine macrophage monocyte cell line was maintained at 37°C and at 5% CO₂ in Dulbecco's modified Eagle's medium (Gibco-BRL, Gaithersburg, MD, USA) with 10% fetal bovine serum (Gibco-BRL). The RAW 264.7 cells were plated at a density of 2.0x10⁵ cells/well and incubated overnight. *Asarum* extracts (2, 10 and 50 µM) or aspirin (50 µM) were then added. Following 2 h of exposure, lipopolysaccharide (LPS) was added to the treated cells at a final concentration of 0.5 µg/ml. The resultant cell lysates were immunoblotted using affinity-purified antibodies against IKKβ, phospho-IKKβ, IκB, phospho-IκB, P65, P65, phospho-P65, phospho-ERK and phospho-JNK (9,10).

**Western blot analysis.** Following treatment, the cells were washed three times with phosphate-buffered saline (PBS), transferred into a 100 µl loading buffer [10 mm Tris-HCl, pH 6.8, glycerol 2%, bromophenol blue 2%, sodium dodecyl sulfate (SDS) 0.4% and mercaptoethanol 0.14%] and incubated on ice for 30 min. For western blotting, the protein of the cell lysate was separated in 10% SDS-PAGE gel and transferred onto nitrocellulose membranes. After blocking with 5% bovine serum albumin (BSA) for 2 h at room temperature, the membranes were washed three times with Tris-HCl buffer solution containing Tween-20 (TBST). The membranes were then incubated with the primary antibodies overnight at 4°C. The membranes were washed and then incubated with horseradish peroxidase-conjugated secondary mouse or rabbit antibodies. The BSA and antibodies were suspended in TBST.

**Statistical analysis.** Values are presented as the mean ± standard deviation. Statistical analysis was performed using a two-tailed Student's t-test, and P<0.05 was considered to indicate a statistically significant difference. Calculations were performed by using SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

**AI.** From day 14, a statistically significant (P<0.05) increase in AI was observed in the FCA-induced arthritic animals in the disease control group compared to the normal control group, as in previous study (11). Treatment with *Asarum* extract at 40 and 80 mg/kg yielded significant (P<0.05) reductions in the swelling pain scores compared with those in the disease control group after 30 days, as shown in Table I.

**Rate of swelling.** Table II shows the rate of swelling. In AA rats compared with normal animals, *Asarum* extract at 40 and 80 mg/kg diminished the rate of swelling.
A significant (P<0.01) increase in the spleen index of the FCA-induced arthritic animals was observed in the disease control group compared with the normal control group. Administration of *Asarum* extract caused a reduction in the spleen index of FCA-induced arthritic rats. Specifically, *Asarum* extract at 40 and 80 mg/kg significantly decreased the spleen index compared with that in the disease control group (P<0.05, P<0.01; Fig. 1).

**IL-1β, IL-6 and TNF-α expression levels.** IL-1β, IL-6 and TNF-α expression levels were detected using a standard ELISA (12-14), and are presented in Table III. Rats with FCA-induced arthritis had significantly (P<0.01) increased IL-1β, IL-6 and TNF-α expression levels compared with those in the normal control group. However, administration of *Asarum* extract or GTW caused significant reductions in the IL-1β, IL-6 and TNF-α expression levels.

**Mitogen-activated protein kinase (MAPK) signaling pathway.** Western blot analysis was performed to evaluate the phosphorylation of MAPK (15,16). Fig. 2 demonstrates that the expression of phosphorylated ERK and p38-MAPK increased in the LPS-induced RAW 264.7 cells. *Asarum* extract (10 and 50 µM) significantly decreased the phosphorylation of ERK and p38, but not JNK (data not shown). Aspirin administration did not cause significant changes in the phosphorylation levels of ERK and p38.
Nuclear factor (NF)-κB signaling pathway. Phosphorylated IkB and P65 expression levels increased in LPS-induced RAW264.7 cells (16-18). Asarum extract at 2, 10 and 50 µM significantly decreased the phosphorylation of IkB and P65. Aspirin had no significant effect on the phosphorylation of IkB and P65 (Fig. 3).

Discussion

RA is an autoimmune disease characterized by multi-joint arthritis and joint erosion, which involves inflammation and immunity, and may be inherited. However, the mechanisms of RA have not been clearly elucidated. AA is an experimental model induced by BCG that is recognized as 65 kDa anti-heat shock protein (HSP65). HSP65 is similar to the conservative sequences in AA rat auto-antigens as HSP65 introduces an autoimmune response by activating T-cell clones. Therefore, AA model rats, which have characteristics similar to those of RA, are the ideal animal model for RA (19).

Joint swelling and pain are the initial manifestations of RA. The podarthrum of the arthritis group animals revealed swelling following injection, and symptoms developed with time. Disease severity was evaluated objectively by measuring the toe volume and by grading the swelling score. Fourteen days following model establishment, the animals in the GTW and all the Asarum extract groups demonstrated an alleviation of secondary symptoms to varying degrees. Toe volume and swelling score decreased, indicating an improvement in AA rats.

The AA model is an immune hyperfunctional model, and spleen hyperplasia has been previously reported in AA model rats (20). In the present study, 40 mg/kg/day GTW and 40 or 80 mg/kg/day Asarum extract were found to significantly reduce spleen hyperplasia (P<0.05, versus model group); however, spleen hyperplasia remained higher compared with that in normal animals. This finding suggests that Asarum extract may help in the recovery of the hyperfunctioning of immune organs without causing damage. Another pro-inflammatory cytokine, TNF-α, is produced by monocytes and macrophages, as well as by T lymphocytes and neutrophils. Release of TNF-α not only causes an inflammatory response, but also induces the production of IL-1β and IL-6 by macrophages, thereby aggravating local inflammatory responses. IL-6 transforms B lymphocyte precursors into antibodies, thus producing mature B lymphocytes, promoting growth and differentiation of bone marrow cells in cooperation with colony stimulating factors and improving the degradation function of natural killer cells (22). In the present study, the expression levels of TNF-α, IL-6 and IL-1β in the plasma of the model animals were higher compared with those in normal animals, whilst Asarum extract decreased serum inflammatory cytokines to varying degrees. These results indicate that Asarum extract reduces the inflammatory response of AA model rats by inhibiting pro-inflammatory factors, which in turn relieve joint damage.

Numerous cytokines and inflammatory factors are involved in the inflammatory response and have various roles through different pathways, including the MAPK and NF-κB pathways (23-25). The nuclear transcription factor NF-κB is involved in inflammation. During the resting condition, NF-κB is inhibited by the binding of IkB and remains in the cytoplasm in default mode. IkB is a p65/p50 inhibitor, and stimulation through LPS induces phosphorylation of IkB kinase, leading to polyubiquitination and degradation of IkB, as well as the release of p65/60 protein. P65/60 protein moves into the cell nucleus and binds to DNA, activating gene transcription and producing multiple inflammatory factors that are involved in RA. The MAPK signaling pathway regulates the gene expression of a number of cytokines, chemotactic factors, growth factors, adherence factors and other enzymes. This pathway also participates in immune and inflammation reactions and has a vital role in cell proliferation, differentiation and apoptosis (26). The results obtained in the present study demonstrated that Asarum extract significantly increases the phosphorylation of IKKβ, IkB and p65, which results in the activation of the NF-κB signaling pathway. Asarum extract was also found to significantly inhibit the phosphorylation of P38 and ERK, thereby blocking the activation of the MAPK signaling pathway. The combined inhibition of the two pathways may prevent the inflammatory response, which may be...
the mechanism by which Asarum extract inhibits AA progression.

These findings indicate that Asarum extract is a potential therapeutic agent for AA as it exerts an anti-inflammatory effect by mediating the NF-κB and MAPK signaling pathways.

References

1. Miossec P: Rheumatoid arthritis: still a chronic disease. Lancet 381: 884-886, 2013.
2. Ogrendik M: Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens. Int J Gen Med 6: 383-386, 2013.
3. Xue M, Jiang ZZ, Wu T, et al: Anti-inflammatory effects and hepatotoxicity of Tripterygium-loaded solid lipid nanoparticles on adjuvant-induced arthritis in rats. Phytomedicine 19: 998-1006, 2012.
4. Stahl EA, Raychaudhuri S, Remmers EF, et al: Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508-514, 2010.
5. Saratha V and Subramanian SP: Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats. Inflammopharmacology 20: 27-37, 2012.
6. Jiangsu New Medicine College: Zhong Yao Da Ci Dian (Dictionary of Chinese Materia Medica). Shanghai Scientific and Technological Publishers, Shanghai, China, p1034, 1977 (In Chinese).
7. Han J, Sun CL and Ji MS: Recent advance of Chinese herb - Asarum. Chinese Agricultural Science Bulletin 27: 46-50, 2011 (In Chinese).
8. Shi XD, Han L, Jia B, Shen T, Peng C, You FM and Liu XL: Effect of serum containing Asarum heterotropoids on Na+ transporter in cardiac myocyte in rats; Zhejiang Journal of Integrated Traditional Chinese and Western Medicine 19: 599-602, 2009 (In Chinese).
9. Cho EJ, An HJ, Shin JS, et al: Roxatidine suppresses inflammatory responses via inhibition of NF-kappaB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem 112: 3648-3659, 2011.
10. Park HH, Kim MJ, Li Y, et al: Britain suppresses LPS-induced nitric oxide, PGE2 and cytokine production via NF-kappaB and MAPK inactivation in RAW 264.7 cells. Int Immunopharmacol 15: 296-302, 2013.
11. Fan AY, Lao L, Zhang RX, et al: Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on adjuvant-induced arthritis in Lewis rats. J Ethnopharmacol 101: 104-109, 2005.
12. Nagai N and Ito Y: Therapeutic effects of gel ointments containing tranilast nanoparticles on paw edema in adjuvant-induced arthritis rats. Biol Pharm Bull 37: 96-104, 2014.
13. Wei ZF, Jiao XL, Wang T, et al: Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE2(2), and MMP-13 expression. Acta Pharmacol Sin 34: 403-413, 2013.
14. Yu KT, Nuss G, Boyce R, et al: Inhibition of IL-1 release from human monocytes and suppression of streptococcal cell wall and adjuvant-induced arthritis in rats by an extract of Tripterygium wilfordii Hook. Gen Pharmacol 25: 1115-1122, 1994.
15. Zha J, Luo C, Wang P, et al: Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells. Exp Ther Med 5: 1345-1350, 2013.
16. Reddy DB and Reddanna P: Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. Biochem Biophys Res Commun 381: 112-117, 2009.
17. Park WS, Jung WK, Lee DY, et al: Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine production of interleukin-6 in fibroblast-like synoviocytes from adjuvant-induced arthritis rats through PKC/MAPK/NF-κB signaling. Inflammopharmacology 20: 27-37, 2012.
18. Issekutz AC and Sapru K: Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int Immunopharmacol 8: 708-716, 2008.
19. Md Yusof MY and Emery P: Targeting interleukin-6 in rheumatoid arthritis. Drugs 73: 341-356, 2013.
20. Joosten LA, Netea MG and Dinarello CA: Interleukin-1β in innate inflammation, autophagy and immunity. Semin Immunol 25: 316-324, 2013.
21. Wei ZF, Jiao XL, Wang T, et al: Norisoboldine inhibits the production of interleukin-6 in fibroblast-like synoviocytes from adjuvant arthritis rats through PKC/MAPK/NF-κB/p38/CREB pathways. J Cell Biochem 113: 2785-2795, 2012.
22. Yang M, Xiao C, Wu Q, et al: Anti-inflammatory effect of Sanshuibaihu decoction may be associated with nuclear factor-kappa B and p38 MAPK alpha in collagen-induced arthritis in rat. J Ethnopharmacol 127: 264-273, 2010.
23. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.